Statins in coronavirus outbreak: It's time for experimental and clinical studies.
作者信息
Bifulco Maurizio, Gazzerro Patrizia
机构信息
Department of Molecular Medicine and Medical Biotechnologies, University of Naples "Federico II", 80131, Naples, Italy.
Department of Pharmacy, University of Salerno, 84084, Fisciano, SA, Italy.
出版信息
Pharmacol Res. 2020 Jun;156:104803. doi: 10.1016/j.phrs.2020.104803. Epub 2020 Apr 11.
Abstract
摘要
相似文献
1
Statins in coronavirus outbreak: It's time for experimental and clinical studies.冠状病毒爆发中的他汀类药物：是时候进行实验和临床研究了。
Pharmacol Res. 2020 Jun;156:104803. doi: 10.1016/j.phrs.2020.104803. Epub 2020 Apr 11.
2
Is the type of diabetes treatment relevant to outcome of COVID-19?糖尿病治疗类型与新型冠状病毒肺炎的预后有关吗？
J Diabetes. 2020 Jul;12(7):486-487. doi: 10.1111/1753-0407.13047.
3
Statin therapy and SAR-COV-2: an available and potential therapy?他汀类药物治疗与新型冠状病毒2：一种可行且有潜力的治疗方法？
Eur Heart J Cardiovasc Pharmacother. 2020 Sep 1;6(5):333-334. doi: 10.1093/ehjcvp/pvaa050.
4
Therapeutic options for the treatment of 2019-novel coronavirus: An evidence-based approach.2019新型冠状病毒治疗的治疗选择：循证方法
Indian J Pharmacol. 2020 Jan-Feb;52(1):1-5. doi: 10.4103/ijp.IJP_119_20. Epub 2020 Mar 11.
5
COVID-19 and relative angiotensin-converting enzyme 2 deficiency: role in disease severity and therapeutic response.新型冠状病毒肺炎与相对血管紧张素转换酶2缺乏：在疾病严重程度和治疗反应中的作用
Open Heart. 2020 Jun;7(1). doi: 10.1136/openhrt-2020-001302.
6
Sofosbuvir for COVID-19 infection: A potential candidate.索磷布韦用于治疗新型冠状病毒肺炎感染：一个潜在的候选药物。
Indian J Pharmacol. 2020 May-Jun;52(3):232-233. doi: 10.4103/ijp.IJP_675_20. Epub 2020 Aug 4.
7
Ivermectin may be a clinically useful anti-inflammatory agent for late-stage COVID-19.伊维菌素可能是一种对晚期新冠肺炎有临床实用价值的抗炎药。
Open Heart. 2020 Sep;7(2). doi: 10.1136/openhrt-2020-001350.
8
Atrial Fibrillation in COVID-19: From Epidemiological Association to Pharmacological Implications.新型冠状病毒肺炎相关心房颤动：从流行病学关联到药物治疗意义。
J Cardiovasc Pharmacol. 2020 Aug;76(2):138-145. doi: 10.1097/FJC.0000000000000854.
9
Deep venous thrombosis in a non-critically ill patient with novel COVID-19 infection.新型冠状病毒感染非危重症患者的深静脉血栓形成。
Thromb Res. 2020 Aug;192:27-28. doi: 10.1016/j.thromres.2020.05.015. Epub 2020 May 14.
10
COVID-19 update: Covid-19-associated coagulopathy.新型冠状病毒肺炎最新情况：新型冠状病毒肺炎相关凝血病
J Thromb Thrombolysis. 2020 Jul;50(1):54-67. doi: 10.1007/s11239-020-02134-3.
引用本文的文献
1
Rosuvastatin accelerates the healing process of partial-thickness burn wounds in rats by reducing TNF-α levels.瑞舒伐他汀通过降低肿瘤坏死因子-α水平加速大鼠浅度烧伤创面的愈合过程。
Arch Med Sci Atheroscler Dis. 2024 Dec 31;9:e226-e240. doi: 10.5114/amsad/196825. eCollection 2024.
2
Time-dependent propensity-matched general population study of the effects of statin use on cancer risk in an interstitial lung disease and pulmonary fibrosis cohort.时间依赖性倾向匹配的一般人群研究他汀类药物使用对间质性肺病和肺纤维化队列中癌症风险的影响。
BMJ Open. 2021 Oct 11;11(10):e047039. doi: 10.1136/bmjopen-2020-047039.
3
The role of lovastatin in the attenuation of COVID-19.洛伐他汀在减轻 COVID-19 方面的作用。
Int Immunopharmacol. 2021 Dec;101(Pt A):108192. doi: 10.1016/j.intimp.2021.108192. Epub 2021 Sep 24.
4
Design and rationale of the colchicine/statin for the prevention of COVID-19 complications (COLSTAT) trial.秋水仙素/他汀类药物预防 COVID-19 并发症（COLSTAT）试验的设计和原理。
Contemp Clin Trials. 2021 Nov;110:106547. doi: 10.1016/j.cct.2021.106547. Epub 2021 Aug 28.
5
Pathomechanisms, therapeutic targets and potent inhibitors of some beta-coronaviruses from bench-to-bedside.一些从实验室到临床的β冠状病毒的发病机制、治疗靶点和有效抑制剂。
Infect Genet Evol. 2021 Sep;93:104944. doi: 10.1016/j.meegid.2021.104944. Epub 2021 May 28.
6
Lipid homeostasis and mevalonate pathway in COVID-19: Basic concepts and potential therapeutic targets.新型冠状病毒肺炎中的脂质稳态和甲羟戊酸途径：基本概念和潜在治疗靶点。
Prog Lipid Res. 2021 Apr;82:101099. doi: 10.1016/j.plipres.2021.101099. Epub 2021 Apr 26.
7
Drug design and repurposing with DockThor-VS web server focusing on SARS-CoV-2 therapeutic targets and their non-synonym variants.利用 DockThor-VS 网络服务器进行药物设计和再利用，重点关注 SARS-CoV-2 的治疗靶点及其非同义变体。
Sci Rep. 2021 Mar 10;11(1):5543. doi: 10.1038/s41598-021-84700-0.
8
Association between antecedent statin use and decreased mortality in hospitalized patients with COVID-19.COVID-19 住院患者中使用他汀类药物前史与死亡率降低的关联。
Nat Commun. 2021 Feb 26;12(1):1325. doi: 10.1038/s41467-021-21553-1.
9
In-hospital use of statins is associated with a reduced risk of mortality in coronavirus-2019 (COVID-19): systematic review and meta-analysis.住院期间使用他汀类药物与降低 2019 年冠状病毒病（COVID-19）死亡率相关：系统评价和荟萃分析。
Pharmacol Rep. 2021 Jun;73(3):769-780. doi: 10.1007/s43440-021-00233-3. Epub 2021 Feb 20.
10
SAveRUNNER: A network-based algorithm for drug repurposing and its application to COVID-19.SAveRUNNER：一种基于网络的药物重定位算法及其在 COVID-19 中的应用。
PLoS Comput Biol. 2021 Feb 5;17(2):e1008686. doi: 10.1371/journal.pcbi.1008686. eCollection 2021 Feb.
本文引用的文献
1
Atorvastatin restricts the ability of influenza virus to generate lipid droplets and severely suppresses the replication of the virus.阿托伐他汀限制了流感病毒生成脂滴的能力，并严重抑制了病毒的复制。
FASEB J. 2019 Aug;33(8):9516-9525. doi: 10.1096/fj.201900428RR. Epub 2019 May 24.
2
Modulation of sterol biosynthesis regulates viral replication and cytokine production in influenza A virus infected human alveolar epithelial cells.固醇生物合成的调节可调控甲型流感病毒感染的人肺泡上皮细胞中的病毒复制和细胞因子产生。
Antiviral Res. 2015 Jul;119:1-7. doi: 10.1016/j.antiviral.2015.04.005. Epub 2015 Apr 13.
3
Mechanisms of action and efficacy of statins against influenza.他汀类药物抗流感的作用机制及疗效
Biomed Res Int. 2014;2014:872370. doi: 10.1155/2014/872370. Epub 2014 Nov 11.
4
Statin: new life for an old drug.他汀类药物：旧药新用途。
Pharmacol Res. 2014 Oct;88:1-2. doi: 10.1016/j.phrs.2014.06.005. Epub 2014 Jul 14.
5
Systematic review and meta-analysis on the association between outpatient statins use and infectious disease-related mortality.系统评价和荟萃分析：门诊使用他汀类药物与感染性疾病相关死亡率的关系。
PLoS One. 2012;7(12):e51548. doi: 10.1371/journal.pone.0051548. Epub 2012 Dec 17.
6
Statins and prevention of infections: systematic review and meta-analysis of data from large randomised placebo controlled trials.他汀类药物与感染预防：来自大型随机安慰剂对照试验的系统评价和荟萃分析数据。
BMJ. 2011 Nov 29;343:d7281. doi: 10.1136/bmj.d7281.
7
Influenza and COPD mortality protection as pleiotropic, dose-dependent effects of statins.流感和慢性阻塞性肺疾病死亡率的保护作用是他汀类药物的多效性、剂量依赖性效应。
Chest. 2007 Apr;131(4):1006-12. doi: 10.1378/chest.06-1997.
Zotero 插件